Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DMRA NASDAQ:LNTH NASDAQ:SYRE NASDAQ:TGTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDMRADamora Therapeutics, Inc. Common Stock$25.30$25.13$2.45▼$38.33$1.56B1.5336,501 shs166,300 shsLNTHLantheus$103.00$84.07$47.25▼$103.89$6.71B-0.081.04 million shs2.02 million shsSYRESpyre Therapeutics$74.05$61.18$13.93▼$78.80$6.43B3.121.14 million shs574,914 shsTGTXTG Therapeutics$38.87$35.46$25.28▼$44.65$5.95B1.682.24 million shs1.36 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDMRADamora Therapeutics, Inc. Common Stock0.00%+2.85%+2.22%-15.04%+738.03%LNTHLantheus0.00%+9.68%+22.14%+40.29%+39.45%SYRESpyre Therapeutics0.00%-1.16%+6.29%+67.61%+393.34%TGTXTG Therapeutics0.00%-1.59%+6.14%+27.15%+12.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDMRADamora Therapeutics, Inc. Common Stock$25.30$25.13$2.45▼$38.33$1.56B1.5336,501 shs166,300 shsLNTHLantheus$103.00$84.07$47.25▼$103.89$6.71B-0.081.04 million shs2.02 million shsSYRESpyre Therapeutics$74.05$61.18$13.93▼$78.80$6.43B3.121.14 million shs574,914 shsTGTXTG Therapeutics$38.87$35.46$25.28▼$44.65$5.95B1.682.24 million shs1.36 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDMRADamora Therapeutics, Inc. Common Stock0.00%+2.85%+2.22%-15.04%+738.03%LNTHLantheus0.00%+9.68%+22.14%+40.29%+39.45%SYRESpyre Therapeutics0.00%-1.16%+6.29%+67.61%+393.34%TGTXTG Therapeutics0.00%-1.59%+6.14%+27.15%+12.44%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDMRADamora Therapeutics, Inc. Common Stock 2.88Moderate Buy$43.4071.54% UpsideLNTHLantheus 2.73Moderate Buy$99.71-3.19% DownsideSYRESpyre Therapeutics 3.00Buy$90.2521.88% UpsideTGTXTG Therapeutics 2.57Moderate Buy$52.5035.07% UpsideCurrent Analyst Ratings BreakdownLatest DMRA, SYRE, LNTH, and TGTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2026SYRESpyre Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$102.005/11/2026LNTHLantheus Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$98.00 ➝ $115.005/8/2026LNTHLantheus CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/8/2026LNTHLantheus Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$85.00 ➝ $115.005/8/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$95.00 ➝ $100.005/7/2026LNTHLantheus The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$94.005/6/2026TGTXTG Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $70.005/6/2026SYRESpyre Therapeutics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$92.00 ➝ $107.005/6/2026SYRESpyre Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$64.00 ➝ $97.005/1/2026TGTXTG Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Hold (C+)5/1/2026LNTHLantheus B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 5/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDMRADamora Therapeutics, Inc. Common StockN/AN/AN/AN/A$6.16 per shareN/ALNTHLantheus$1.54B4.35$6.39 per share16.13$18.62 per share5.53SYRESpyre Therapeutics$890K7,225.28N/AN/A$5.93 per share12.49TGTXTG Therapeutics$616.29M9.65$2.80 per share13.87$3.81 per share10.20Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDMRADamora Therapeutics, Inc. Common Stock-$209.84M-$5.58N/AN/AN/AN/A-428.30%-114.62%8/5/2026 (Estimated)LNTHLantheus$233.56M$4.1524.8219.18N/A18.05%29.32%15.00%8/5/2026 (Estimated)SYRESpyre Therapeutics-$155.20M-$2.08N/AN/AN/AN/A-42.88%-27.76%8/4/2026 (Estimated)TGTXTG Therapeutics$447.18M$2.8613.5913.98N/A65.95%88.73%43.44%8/3/2026 (Estimated)Latest DMRA, SYRE, LNTH, and TGTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026DMRADamora Therapeutics, Inc. Common Stock-$0.3878-$0.62-$0.2322-$0.62N/AN/A5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million5/6/2026Q1 2026TGTXTG Therapeutics$0.23$0.12-$0.11$0.12$200.33 million$204.92 million5/5/2026Q1 2026SYRESpyre Therapeutics-$0.66-$0.74-$0.08-$0.74$70.87 millionN/A2/26/2026Q4 2025LNTHLantheus$1.17$1.67+$0.50$0.82$367.03 million$406.79 million2/26/2026Q4 2025TGTXTG Therapeutics$0.35$0.14-$0.21$0.14$192.15 million$192.57 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDMRADamora Therapeutics, Inc. Common StockN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDMRADamora Therapeutics, Inc. Common StockN/A22.4922.48LNTHLantheus0.472.832.64SYRESpyre TherapeuticsN/A8.978.97TGTXTG Therapeutics1.285.815.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDMRADamora Therapeutics, Inc. Common Stock14.20%LNTHLantheus99.06%SYRESpyre Therapeutics80.39%TGTXTG Therapeutics58.58%Insider OwnershipCompanyInsider OwnershipDMRADamora Therapeutics, Inc. Common Stock0.40%LNTHLantheus1.70%SYRESpyre Therapeutics15.69%TGTXTG Therapeutics10.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDMRADamora Therapeutics, Inc. Common Stock4061.55 million61.31 millionNo DataLNTHLantheus1,19365.11 million64.00 millionOptionableSYRESpyre Therapeutics7386.84 million73.22 millionOptionableTGTXTG Therapeutics290153.08 million136.80 millionOptionableDMRA, SYRE, LNTH, and TGTX HeadlinesRecent News About These CompaniesTG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 25 at 4:14 AM | americanbankingnews.comMultiple sclerosis-focused biotech quadruples its profit, raises sales forecastMay 22 at 1:15 PM | msn.comTGTX Stock Rises 29% in 3 Months: Here's What You Should KnowMay 20, 2026 | zacks.comTG Therapeutics (NASDAQ:TGTX) Shares Pass Above 200-Day Moving Average - Here's What HappenedMay 19, 2026 | americanbankingnews.comTG Therapeutics Stock Story Gains Interest In Nasdaq IndexMay 13, 2026 | kalkinemedia.comKTG Therapeutics' (NASDAQ:TGTX) Earnings Aren't As Good As They AppearMay 13, 2026 | finance.yahoo.comHistoric Signal Says This Biotech OutperformsMay 11, 2026 | schaeffersresearch.comWhy TG Therapeutics (TGTX) Is Up 27.4% After Raising 2026 Revenue Guidance On BRIUMVI StrengthMay 11, 2026 | finance.yahoo.comAssessing TG Therapeutics (TGTX) Valuation After Recent Share Price MomentumMay 10, 2026 | finance.yahoo.comQ2 EPS Estimates for TG Therapeutics Increased by AnalystMay 8, 2026 | marketbeat.comTGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 ViewMay 7, 2026 | zacks.comTG Therapeutics Q1 Earnings Call HighlightsMay 7, 2026 | marketbeat.comTG Therapeutics: Q1 Earnings SnapshotMay 6, 2026 | seattlepi.comSTG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue GuidanceMay 6, 2026 | markets.businessinsider.comTG Therapeutics (TGTX) Q1 2026 Earnings TranscriptMay 6, 2026 | finance.yahoo.comTGTX stock hits fresh 52-week high – here’s why retail is bullish despite Q1 earnings missMay 6, 2026 | msn.comTG Therapeutics (NASDAQ:TGTX) Issues Quarterly Earnings ResultsMay 6, 2026 | marketbeat.comTG Therapeutics (NASDAQ:TGTX) Reaches New 1-Year High - Time to Buy?May 6, 2026 | marketbeat.comTG Therapeutics (TGTX) Q1 Earnings Lag EstimatesMay 6, 2026 | zacks.comVanguard Group Inc. Has $472.22 Million Stock Position in TG Therapeutics, Inc. $TGTXMay 6, 2026 | marketbeat.comTG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue GuidanceMay 6, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDMRA, SYRE, LNTH, and TGTX Company DescriptionsDamora Therapeutics, Inc. Common Stock NASDAQ:DMRA$25.30 0.00 (0.00%) As of 05/22/2026 04:00 PM EasternGalecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.Lantheus NASDAQ:LNTH$103.00 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$101.75 -1.25 (-1.21%) As of 05/22/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Spyre Therapeutics NASDAQ:SYRE$74.05 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$73.40 -0.65 (-0.88%) As of 05/22/2026 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.TG Therapeutics NASDAQ:TGTX$38.87 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$38.85 -0.02 (-0.05%) As of 05/22/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
